Mesoblast Limited - American Depositary Shares (MESO)
13.10
-0.55 (-4.03%)
NASDAQ · Last Trade: Nov 12th, 11:51 PM EST
Detailed Quote
Previous Close
13.65
Open
13.29
Bid
11.90
Ask
13.48
Day's Range
13.00 - 13.52
52 Week Range
11.89 - 21.50
Volume
184,226
Market Cap
8.52B
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
286,177
Chart
About Mesoblast Limited - American Depositary Shares (MESO)
Mesoblast Ltd is a biotechnology company focused on developing innovative regenerative medicine therapies aimed at addressing significant unmet medical needs. Utilizing its expertise in cellular therapies, the company is advancing treatments for a range of conditions, including chronic inflammatory and degenerative diseases, as well as certain types of cancer. Mesoblast's pioneering work centers on the use of allogeneic cell products, derived from healthy donors, to harness the body’s natural healing processes, with the goal of improving patient outcomes and quality of life. Through rigorous clinical development programs, the company seeks to bring transformative therapies to market that can change the landscape of treatment for various critical health issues. Read More
Mesoblast (NASDAQ:MESO) reported $115 million in net revenue for fiscal 2026 and said it expects a pivotal trial readout for its experimental chronic low back pain treatment around midyear to the third quarter of calendar 2027.
The company also reported $110 million in gross profit on sales for the
Mesoblast (NASDAQ:MESO) reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company’s FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD.
Chief Executive Of
Mesoblast (NASDAQ:MESO) released full-year financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and
Mesoblast Limited (NASDAQ:MESO) shares are trading higher on Friday after the company announced that Ryoncil received a J-Code from the United States Medicare & Medicaid Services, streamlining billing and payment processes for the product.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Shares of The Greenbrier Companies, Inc. (NYSE: GBX) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for the third quarter. The company posted quarterly earnings of $1.86 per share, beating market estimates of 98 cents per share.